These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 23632889

  • 1. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
    Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA.
    Blood; 2013 Jun 27; 121(26):5192-202. PubMed ID: 23632889
    [Abstract] [Full Text] [Related]

  • 2. Imatinib tackles lymphoma via the PDGFRβ+ pericyte.
    Chute JP, Himburg HA.
    Blood; 2013 Jun 27; 121(26):5107-8. PubMed ID: 23813934
    [No Abstract] [Full Text] [Related]

  • 3. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C.
    Int J Cancer; 2007 Dec 15; 121(12):2606-14. PubMed ID: 17691110
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y, Jia L, Wang X, Tan X, Xu J, Deng Z, Jiang T, Rainov NG, Li B, Ren H.
    Int J Oncol; 2011 Feb 15; 38(2):555-69. PubMed ID: 21152856
    [Abstract] [Full Text] [Related]

  • 7. Expression of platelet-derived growth factor receptor β is maintained by Prox1 in lymphatic endothelial cells and is required for tumor lymphangiogenesis.
    Miyazaki H, Yoshimatsu Y, Akatsu Y, Mishima K, Fukayama M, Watabe T, Miyazono K.
    Cancer Sci; 2014 Sep 15; 105(9):1116-23. PubMed ID: 24981766
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potentiation of platelet-derived growth factor receptor-β signaling mediated by integrin-associated MFG-E8.
    Motegi S, Garfield S, Feng X, Sárdy M, Udey MC.
    Arterioscler Thromb Vasc Biol; 2011 Nov 15; 31(11):2653-64. PubMed ID: 21868707
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
    Kinoshita K, Nakagawa K, Hamada J, Hida Y, Tada M, Kondo S, Moriuchi T.
    Int J Oncol; 2010 Oct 15; 37(4):869-77. PubMed ID: 20811709
    [Abstract] [Full Text] [Related]

  • 12. A differential role for CD248 (Endosialin) in PDGF-mediated skeletal muscle angiogenesis.
    Naylor AJ, McGettrick HM, Maynard WD, May P, Barone F, Croft AP, Egginton S, Buckley CD.
    PLoS One; 2014 Oct 15; 9(9):e107146. PubMed ID: 25243742
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells.
    Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK.
    J Cell Biochem; 2006 Dec 15; 99(6):1553-63. PubMed ID: 16817200
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological PDGFRβ inhibitors imatinib and sunitinib cause human brain pericyte death in vitro.
    King NE, Courtney JM, Brown LS, Foster CG, Cashion JM, Attrill E, Premilovac D, Howells DW, Sutherland BA.
    Toxicol Appl Pharmacol; 2022 Jun 01; 444():116025. PubMed ID: 35443205
    [Abstract] [Full Text] [Related]

  • 15. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β.
    Ohishi J, Aoki M, Nabeshima K, Suzumiya J, Takeuchi T, Ogose A, Hakozaki M, Yamashita Y, Iwasaki H.
    BMC Cancer; 2013 May 04; 13():224. PubMed ID: 23642185
    [Abstract] [Full Text] [Related]

  • 16. Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth.
    Thijssen VL, Paulis YW, Nowak-Sliwinska P, Deumelandt KL, Hosaka K, Soetekouw PM, Cimpean AM, Raica M, Pauwels P, van den Oord JJ, Tjan-Heijnen VC, Hendrix MJ, Heldin CH, Cao Y, Griffioen AW.
    J Pathol; 2018 Dec 04; 246(4):447-458. PubMed ID: 30101525
    [Abstract] [Full Text] [Related]

  • 17. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
    Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ.
    J Natl Cancer Inst; 2006 Jun 07; 98(11):783-93. PubMed ID: 16757703
    [Abstract] [Full Text] [Related]

  • 18. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma.
    Zhang JB, Sun HC, Jia WD, Zhuang PY, Qian YB, Zhu XD, Kong LQ, Wang L, Wu WZ, Tang ZY.
    BMC Cancer; 2012 Oct 01; 12():439. PubMed ID: 23025904
    [Abstract] [Full Text] [Related]

  • 19. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
    Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM.
    Cancer Res; 2009 May 15; 69(10):4527-36. PubMed ID: 19401451
    [Abstract] [Full Text] [Related]

  • 20. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats.
    Schellings MW, Baumann M, van Leeuwen RE, Duisters RF, Janssen SH, Schroen B, Peutz-Kootstra CJ, Heymans S, Pinto YM.
    Hypertension; 2006 Mar 15; 47(3):467-74. PubMed ID: 16432052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.